EG18335A - Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis - Google Patents

Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis

Info

Publication number
EG18335A
EG18335A EG53/88A EG5388A EG18335A EG 18335 A EG18335 A EG 18335A EG 53/88 A EG53/88 A EG 53/88A EG 5388 A EG5388 A EG 5388A EG 18335 A EG18335 A EG 18335A
Authority
EG
Egypt
Prior art keywords
hyperlipidaemia
treatment
pyridoxine
antherosclerosis
prevention
Prior art date
Application number
EG53/88A
Original Assignee
Speck Ulrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Speck Ulrich filed Critical Speck Ulrich
Application granted granted Critical
Publication of EG18335A publication Critical patent/EG18335A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Pyridoxine derivatives and their salts, in particular pyridoxal, pyridoxal phosphate, pyridoxamine and pyridoxamine phosphate, are used in the prophylaxis and treatment of hyperlipidaemia and atherosclerosis. Exceptions are pyridoxine-5'-phosphoric acid glutamate and aspartate, which are described in DE 2,461,742 C2. Natural, highly compatible, chemically unambiguously described and adequately stable substances having good activity for long term treatments are thereby made available. The buccal administration form and enteric-resistant forms have proved particularly suitable.
EG53/88A 1987-02-18 1988-02-01 Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis EG18335A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873705549 DE3705549A1 (en) 1987-02-18 1987-02-18 USE OF PYRIDOXINE DERIVATIVES IN THE PROPHYLAXIS AND THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS

Publications (1)

Publication Number Publication Date
EG18335A true EG18335A (en) 1992-09-30

Family

ID=6321453

Family Applications (1)

Application Number Title Priority Date Filing Date
EG53/88A EG18335A (en) 1987-02-18 1988-02-01 Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis

Country Status (12)

Country Link
EP (1) EP0282696B1 (en)
JP (2) JPH0710777B2 (en)
KR (1) KR950009094B1 (en)
AT (1) ATE82125T1 (en)
CA (1) CA1340246C (en)
DE (2) DE3705549A1 (en)
DK (1) DK55888A (en)
EG (1) EG18335A (en)
ES (1) ES2052609T3 (en)
GR (1) GR3006693T3 (en)
HU (1) HUT47850A (en)
ZA (1) ZA88577B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
AU1444600A (en) * 1998-10-09 2000-05-01 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
ATE306489T1 (en) 1999-03-08 2005-10-15 Medicure Inc PYRIDOXAL ANALOGUE FOR THE TREATMENT OF DISORDERS CAUSED BY VITAMIN B6 DEFICIENCY
AU5840200A (en) 1999-07-13 2001-01-30 Medicure Inc. Treatment of diabetes and related pathologies
WO2001013900A2 (en) 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
DE60110054T2 (en) 2000-02-29 2006-03-09 Medicure International Inc. CARDIOPROTECTIVE PHOSPHONATES
US6586414B2 (en) 2000-03-28 2003-07-01 Medicure International Inc. Treatment of cerebrovascular disease
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
NZ523815A (en) 2000-07-07 2004-07-30 Medicure Int Inc Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
AU2004224562A1 (en) * 2003-03-27 2004-10-07 Medicure Inc. Modulation of cell death
WO2006050598A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7375112B2 (en) * 2005-01-05 2008-05-20 Medicure International Inc. Compounds and methods for regulating triglyceride levels
FR3038227B1 (en) 2015-06-30 2018-08-17 Assistance Publique - Hopitaux De Paris EFFERVESCENT FORMULATION BASED ON PYRIDOXAL-5-PHOSPHATE
JP7244024B2 (en) * 2018-06-25 2023-03-22 学校法人近畿大学 Collagen degradation inhibitor for blood vessel walls affected by nicotine intake

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3373E (en) 1904-02-26 1904-10-27 Joseph Louis Felix Garrigou Process for treating emptying and organic waste, and overall apparatus for its implementation
FR6707M (en) * 1966-04-29 1969-02-17
GB1070120A (en) * 1966-05-06 1967-05-24 Tanabe Seiyaku Co Pyridoxine derivative and the preparation thereof
FR7238M (en) * 1968-03-27 1969-09-01
FR2035765A1 (en) 1969-03-06 1970-12-24 Inst Rech Scient Medicaments contg pyridoxine heparinates or - other vitamin b6 heparinates
JPS5347110B2 (en) * 1971-11-02 1978-12-19
FR2176509A2 (en) 1972-03-21 1973-11-02 Inst Rech Scient Pyridoxine p-chlorophenoxyisobutyrate prodn - giving very pure product from corresp acid and pyridoxine
JPS5018470A (en) * 1973-05-31 1975-02-26
FR2260330A1 (en) 1974-02-07 1975-09-05 Innothera Lab Sa Pyridoxine N-oxy nicotinate - hypolipaemiant and hypocholesterolemiant of good therapeutic index
CH607773A5 (en) 1974-12-24 1978-10-31 Steigerwald Arzneimittelwerk Process for the preparation of novel pyridoxine derivatives
DE2461742C2 (en) 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxine-5'-phosphoric acid ester derivatives and their preparation and pharmaceuticals containing these compounds
FR2349330A1 (en) * 1976-04-29 1977-11-25 Savini Emile Compsns. contg. pyridoxine and an antioxidant esp. tocopherol - used for treatment of hyperlipidaemia
JPS5347110A (en) * 1976-10-12 1978-04-27 Osaka Bosui Kensetsusha Kk Impermeable wall forming method

Also Published As

Publication number Publication date
ATE82125T1 (en) 1992-11-15
JPH07238020A (en) 1995-09-12
DK55888A (en) 1988-08-19
KR950009094B1 (en) 1995-08-14
GR3006693T3 (en) 1993-06-30
JPH0710777B2 (en) 1995-02-08
EP0282696A3 (en) 1989-06-14
EP0282696A2 (en) 1988-09-21
KR880009649A (en) 1988-10-04
JPS63203621A (en) 1988-08-23
DE3705549A1 (en) 1988-09-01
ZA88577B (en) 1988-07-28
CA1340246C (en) 1998-12-15
ES2052609T3 (en) 1994-07-16
DK55888D0 (en) 1988-02-03
HUT47850A (en) 1989-04-28
DE3875760D1 (en) 1992-12-17
EP0282696B1 (en) 1992-11-11
JP2588686B2 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
EG18335A (en) Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and antherosclerosis
KR950009098B1 (en) Pharmaceutical composition for use in treating clot formation
AU2490297A (en) Use of strontium salts for the production of pharmaceutical compositions intended for the treatment of arthrosis
HU896498D0 (en) Process for preparation of low volatility salts
AU7316591A (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
DE69230526D1 (en) POLYAMINIC ACID DISPERSING AGENT
DE3273611D1 (en) Infusion solutions for heart therapy
AU2005188A (en) Pharmaceutical composition for intranasal administration comprising gh-releasing hormone, a cholinergic agonist and in case a bile salt
HUT45564A (en) Process for producing hirudine variants
GR900300043T1 (en) Use of the enzyme-cofactor nadph in the preparation of a pharmaceutical, pharmaceutical and preparation thereof
PL306371A1 (en) Diamine salts of clavulanic acid
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
AU639097B2 (en) Medicament for treating hyperlipidaemia and/or atherosclerosis
AU1463888A (en) Nitrification-inhibiting agent
EP0355612A3 (en) New furylthiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
IL81549A0 (en) Pharmaceutical compositions containing glycerophosphoryl-o-serine or a salt thereof,certain such novel salts and their preparation
AU589148B2 (en) Medicament for the treatment of acquired immune deficiency syndrome and corresponding pharmaceutical compositions and method of treatment
EP0286802A3 (en) Use of ofloxacin in treating or preventing locally periodontal disease
HU9200025D0 (en) Medical preparations for treating depression
ZA871140B (en) Synergistic chemical compositions for treating salmonellosis
GB8810322D0 (en) Fine filler for dental purposes
DE3869772D1 (en)
GR3015225T3 (en) Pesticide composition.
IT1174592B (en) Compsn. for treatment of diarrhoea
HU9201483D0 (en) Process for the production of 1h-rh-analogues'acid additive salts, and for the production of medical preparations containing them